Nihan EREN KAHYA, Sadık Volkan EMREN, Hale BÜlBÜL, Sadettin USLU, Serhan ÖZYILDIRIM

Varfarin kullanan hastada travma olmaksızın gelişen alt ekstremite kas hematomu ve VKORC1, CYP2C9 gen polimorfizmi ile ilişkisi

Varfarin günümüzde en sık kullanılan oral antikoagülanajandır. Varfarin yanıtı beslenme alışkanlıkları ve ilaçlargibi çevresel faktörlerin yanında genetik faktörlerdende etkilenebilir ve bu da kanama riskini artırabilir. Buyazıda, düşük doz varfarin kullanmasına rağmen solalt ekstremitede travma olmaksızın hematom gelişenve gen analizlerinde CYP2C9*2*3, VKORC1 AA veVKORC1 TT gen polimorfizmi saptanan 79 yaşında birerkek hasta sunuldu.

Nontraumatic muscular hematoma of lower extremity in a patient using warfarin and its relationship with VKORC1, CYP2C9 gene polymorphism

Warfarin is the most frequently used oral anticoagulant agenttoday. Warfarin response can be affected by environmentalfactors such as dietary habits and drugs as well as geneticfactors, and this might increase bleeding risk. In thisarticle, we report a 79-year-old male patient who developednontraumatic hematoma of left lower extremity despiteusing low-dose warfarin, and whose genetic analysesrevealed CYP2C9*2*3, VKORC1 AA and VKORC1 TTgene polymorphisms.

PDF

___

1. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, DAngelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-8.
2. DAndrea G, DAmbrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9.
3. DAndrea G, DAmbrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9.
4. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-7.
5. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
6. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005;7:97-104.
7. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007;116:2563-70.
8. Silan C, Dogan OT, Silan F, Kukulguven FM, Asgun HF, Ozdemir S, et al. The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population. Mol Biol Rep 2012;39:11017-22.
9. Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med 2009;150:293-300.
10. Atılgan Z, Tekbaş E, Atılgan S, Yazıcı S, Yavuz C. Warfarin kullanımından kaynaklanan gastroknemius kası hematomu: Atipik yerleşimli hematomlarda genotip analizinin önemi. Turk Gogus Kalp Dama 2012;20:929-31.
11. Sakakibara Y, Aikawa S, Enomoto Y, Osaka M, Hiramatsu Y, Shigeta O, et al. Lower extremity hematoma as a complication of warfarinization in patients with artificial heart valves. Jpn Heart J 1999;40:239-45.